GeoPharma Announces Record Revenues in Third Quart...(inistrative expenses exclusive of deprec...)

and amortization, were $5.3 million for the quarter ended December 2007

as compared to $3.7 million for the quarter ended September 2007.

Increases this quarter were attributable to higher costs related to the

addition of the DYHP acquisition in October 2007 in addition to

additional legal and accounting costs and other business expansion such

as rents, payrolls and related insurances.

-- Research and development ("R&D") expenditures for the three months

ended December 31, 2007 totaled approximately $310,000 all of which was

charged as an expense to operations as compared to $336,000 of R&D

expense for September 2007.

CONFERENCE CALL INFORMATION

GeoPharma will host a conference call to discuss results on Thursday, February 14, 2008 at 11:30 (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Interested parties may participate in the conference call by dialing 1-888-680-0869 and entering pass code 78555682, 5 minutes prior to the initiation of the call. A replay of the conference call will be available from 1:30 PM (ET) on February 14 through February 21, by dialing 1-888-286-8010 and entering pass code 37538422.

Webcast registration (http://phx.corporate- ir.net/phoenix.zhtml?c=120778&p=IROL-Guestbook&UniqueId=1754335&mp=irol- eventDetails&mpdp=EventId~1754335!WebCastId~724916!StreamId~1051110&pp=IROL - BasicWebCast&ppdp=EventId~1754335!WebCastId~724916!StreamId~1051110&pph=339 &pp w=270&rdu)

ABOUT GEOPHARMA, INC.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used
'/>"/>